P1801 / PharmaEssentia - LARVOL DELTA

A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other Cancer. (PubMed, Cancers (Basel)) - "P1801 displayed unique binding properties different from pembrolizumab and nivolumab. Therefore, it showed distinctive immunological reactions and significant antitumor activities. We are initiating a Phase 1 clinical study to test its combination use with ropeginterferon alfa-2b, which also has antiviral and antitumor activities, for the treatment of cancer."

Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Infectious Disease • Oncology • IL2

A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other Cancer (Multidisciplinary Digital Publishing Institute) - "P1801 significantly induced the release of IL-2 from activated T cells but not from nonactivated T cells....In humanized PD-1 mice harboring human PD-L1-expressing colon tumor cells, P1801 administered intraperitoneally twice per week at 12 mg/kg significantly inhibited tumor growth and prolonged mouse survival."

Preclinical • Oncology

[Announcement] Yaohua Pharmaceutical’s PD-1 inhibitor P1801, following the first phase clinical trial of P1101 for the treatment of patients with terminal solid tumors, has applied for human clinical trial review (IND) from the Food and Drug Administration (TFDA) of the Ministry of Health and Welfare. [Google translation] (stock.yahoo) - "Yaohua Pharmaceutical's PD-1 inhibitor P1801, following the first phase clinical trial of P1101 for the treatment of patients with terminal solid tumors, has applied for human clinical trial review (IND) to the Food and Drug Administration (TFDA) of the Ministry of Health and Welfare....The company's new PD-1 inhibitor monoclonal antibody drug P1801 will be used to treat patients with advanced solid tumors following P1101....Subject recruitment for this trial includes two phases, namely the dose escalation phase (Dose Escalation Phase) and Dose Expansion Cohort. The dose escalation phase is expected to be completed in 2025. It is expected that all groups will be completed in 2027."

New P1 trial • Oncology • Solid Tumor